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Background: Fragile X Syndrome (FXS), the most common cause of familiar mental retardation, is associated in
over 99% of cases to an expansion over 200 repeats of a CGG sequence in the 5’ UTR of the FMR1 gene (Xq27.3),
leading to the hypermethylation of the promoter. Molecular diagnosis of FXS have been so far based on the use of
the Southern Blot (SB) analysis, a low throughput and time consuming technique. In order to update the diagnostic
approach for FXS, we evaluated the usefulness of the Methylation-Specific Multiplex-Ligation-dependent Probe
Amplification assay (MS-MLPA).
Methods: The study was carried out by retrospectively analysing 44 male patients, 10 Chorionic Villus Sampling
(CVS) samples and 10 females previously analyzed by SB. In addition, a prospective study on 98 male subjects, 20
females and 1 CVS sample was carried out for assessing the feasibility and the impact of MS-MLPA in a routine lab
work.
Result: Results provided by both the retrospective and the prospective parts of this study strongly demonstrate the
robustness and reproducibility of the MS-MLPA assay, able to correctly detect the methylation status in all normal
and full mutation male samples analyzed, including CVS male samples. On the other hand, MS-MLPA analysis on
females samples produced unreliable results.
Conclusion: Based on our results, we suggest the necessity of a separate workflow for male and female patients
with suspected FXS in the routine diagnostic setting. MS-MLPA, in combination with CGG repeat sizing using a
single-tube primed FMR1 PCR, represents a reliable diagnostic protocol in the molecular diagnosis of FXS male
patients.
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Fragile X Syndrome (FXS) (OMIM #300624) is a com-
mon cause of familial mental retardation (MR) and the
second cause of mental impairment after trisomy 21 in
males, representing about 1% of all MR and 10% of X-
Linked MR [1]. Recent epidemiological studies indicate
that FXS is responsible for moderate to severe mental
retardation in 1:4000–6000 males of European descent;
the same condition is also responsible for mild-to-mo-* Correspondence: v.gatta@unich.it
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reproduction in any medium, provided the orderate mental retardation in 1:7000–10000 females
[2,3]. In affected boys, delay in language acquisition
and/or behavioural problems with frequent occurrences
of autistic-like features and hyperactivity are the main
presenting symptoms. The characteristic clinical signs,
such as mild facial dysmorphism with long face and
large ears, and macroorchidism, are established around
puberty. In the majority of cases (99%), the disease is
associated with an expansion over 200 repeats of the
CGG sequence located in the 5’ UTR of the FMR1 gene
(Xq27.3), leading to the hypermethylation of the pro-
moter. As a consequence, the gene is transcriptionally
silenced and the gene product, the fragile X mental re-
tardation protein (FMRP), is absent [4]. Only repeat
sizes over 200 are associated with full-blown MR as atd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Samples entering in the retrospectives and
prospective MLPA study
MALES Retrospectives Prospectives Total
Normal 17 94 111
Premutation 1 - 1
Full Mutation 23 4 27
Size Mosaicism (Pre/Full) 1 - 1
Methylation Mosaicism 1 - 1
FMR1-FMR2 deletion 1 - 1
TOTAL 44 98 142
FEMALES Retrospectives Prospectives Total
Normal 4 8 12
Premutation 1 5 6
Full Mutation 5 7 12
TOTAL 10 20 30
CVS MALE Foetuses Retrospectives Prospectives Total
Normal 6 1 7
Full Mutation 4 - 4
TOTAL 10 11
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premutations (55–200 repeats) do not affect promoter
methylation and can lead to fragile X-associated Tremor/
Ataxia syndrome (FXTAS) and premature ovarian failure
(POI) in females [4]. Accurate sizing of premutations
by PCR can be hampered by the fact that, despite the
availability of several specific techniques, large expansions
are refractory to PCR amplifications, making alleles
above 120 CGGs difficult to detect. As a consequence,
so far the largest allele that has been amplified by PCR
consists of 250 CGG repeats [5], and the amplification
of alleles larger than 100 repeats is highly variable. The
SB technique is still considered as the gold standard
for the molecular diagnosis of FXS, being able to clearly
distinguish between full mutated and premutated al-
leles and, by digesting DNA with methylation sensitive
enzymes, providing information also regarding the FMR1
promoter methylation status [6]. However, SB is time-
consuming, it requires large amounts of DNA and pos-
sibly the use of radioactive material. Thus the first step
in the molecular diagnosis of FXS in male patients is
represented by a PCR-based analysis, followed by SB on
in cases in which failure of PCR amplification suggests
the presence of a CGG expansion. However, this ap-
proach is sometimes uninformative in females, where
the presence of a single PCR amplification product may
indicate either a condition of homozygosity for two
FMR1 alleles with the same number of CGG repeats or
the presence of a normal and an expanded allele. Re-
cently, a novel, single-tube CGG repeat primed FMR1
PCR (RP-PCR) technology has become available based
on the use of two gene-specific primers flanking the
triplet repeat region and a third primer complementary
to the (CGG)n repeat. This approach provides robust
detection of expanded alleles and resolves allele zygos-
ity, thus minimizing the number of samples requiring
SB analysis and producing more comprehensive FMR1
genotyping data than other methods [7,8]. Since the
distinction between a premutation and a full mutation
is related to the methylation status rather than to the
exact size of the repeat, in the present study we evalu-
ated the usefulness of the Methylation-Specific Multi-
plex-Ligation-dependent Probe Amplification (MS-MLPA)
assay to assess the methylation status of the promoter
of the FMR1 gene for the molecular diagnosis of FXS.
In fact MLPA represent a widely used technique in the
study of gene copy number but also for the assessment
of the methylation status of specific genes [9-14]. This
approach was used in a retrospective study on 44 males,
10 Chorionic Villus Sampling (CVS) samples from male
foetuses and 10 females in order to verify if MS-MLPA
could replace SB in the evaluation of the methylation
status of the promoter of FMR1 gene. Moreover, a pro-
spective study on 98 male samples, 20 females and 1CVS sample was carried out, aimed to the assessment
of the feasibility and the impact of such technique in a
routine lab work.Methods
Patients
The study included 64 retrospective and 119 prospective
samples selected according to clinical criteria and en-
tered in routine diagnosis at the Laboratory of Human
Genetics of Genoa from April to June 2011 (Table 1).
Among retrospective cases, 28 (23 males, 5 females)
were FXS patients carriers of a FMR1 full mutation, 2 (1
male and 1 female) were premutated subjects and 21 (17
males and 4 females) were normal controls. DNA was
obtained from peripheral blood cells using standard pro-
cedures. In addition, 10 CVS from male foetuses with
gestational age ranging from 12 to 17 weeks entered
this study, of which six normal and 4 full mutated male
foetuses. In order to verify the analytical sensitivity of
MS-MLPA technique in the detection of methylation
mosaicism cases, we also tested: i) one FXS patient with
a size mosaicism of premutation/full mutation (pre/
full); ii) one FXS male showing a partially (near to 5%)
methylated full mutation; iii) 6 additional DNA samples
consisting of mixtures of dilution series (100, 75, 50,
25, 10, 5, and 2.5%) of DNA from a full-mutated patient
mixed with DNA from a normal male. The fragile X
genotype of each sample had been previously assessed
using SB and PCR analysis, and MS-MLPA analysis was
performed in blind.
Figure 1 Electropherograms showing the results of MS-MLPA analysis of the FMR1 gene: A,B = normal male; C,D = premutated male;
E,F = full mutated patient. Straight arrows = methylation specific FMR1 probes; Asterisks = digestion control probes.
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number determination in the FXS critical region in de-
letion cases, we analyzed a previously described patient
[15], who carries a microdeletion (approx. 3,2 Mb) in-
volving bands Xq27.3-28 and encompassing SLITRK2,
FMR1 and FMR2 (AFF2) genes.The 119 novel prospective samples were represented
by 98 intellectually disabled males and 1 CVS from male
foetus with suspected FXS and 20 females ( 7 full mutated,
5 premutated and 8 normal controls) (Table 1). In the pro-
spective study, methylation status was investigated by
MS-MLPA, followed by SB study to confirm the results.












(l. inf. – l. sup.)
Males unaffected controls 17 94 0-0.05 0.005 (0.017) 0 0.003-0.005
Males premutation cases 1 - 0-0.02 NA 0
Males full mutation cases 23 4 0.64-1.37 0.89 (0.26) 1 0.867-0.951
Males premut/Full mosaic 1 - 0.48-0.85 0.66 (NA) 0-1 NA
Males methylat. mosaic (5% Full) 1 - 0.04-0.08 0.06 (NA) 0-1 NA
Male foetuses (CVS) normal 6 1 0 NA 0 NA
Male foetuses (CVS) Full mut. 4 - 0.48-1.26 0.73 (0.36) 1 0.609-0.883
Female normal e premutat. 5 13 0.05-0.97 0.46 (0.10) 0.5 0.412-0.508
Female Full mutation cases 5 7 0.1-1.73 0.48 (0.20) 0.75 0.350-0.614
*: digested with HhaI; ** undigested.
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nostic procedure and was approved by patients or their
guardians with a written informed consent. No additional
study has been performed on this material.
MS-MLPA analysis
MS-MLPA analysis was carried out using the SALSA
ME029-B1 FMR1/AFF2 probemix (MRC-Holland) con-
taining 27 probes specific for FMR1 and AFF2 (FMR2)
genes according to the recommendations of the manu-
factures [16]. Fourteen probes in the mixcontain a HhaI
recognition site, 7 of which are specific for the FMR1
promoter. In addition, 13 different reference probes spe-
cific for genes at other locations are present in the kit.Figure 2 Electropherograms showing the results of MS-MLPA analysis o
male methylation mosaic after HhaI digestion; C = mixture of DNA fro
male (95%). Left: methylation specific FMR1 probes (straight arrow). Right:Each MS-MLPA reaction generates two products: one
undigested product for copy number detection and one
digested product for methylation detection. After MS-
MLPA reaction, the samples were loaded onto an ABI
3130xl (Applied Biosystems) using POP7.
MS-MLPA data analysis
Signals produced by MS-MLPA reactions were captured
by Gene Mapper 3.2 and the specific peak area values
were reported in an Excel spreadsheet. The presence of
aberrant methylation was identified in these samples by
the appearance after HhaI digestion of a signal peak that
was absent in unmethylated normal controls. The diag-
nosis of FMR1 deletions was based on the absence off the FMR1 gene: A = male methylation mosaic, undigested; B =
m a full-mutated patient (5%) mixed with DNA from a normal
digestion control probes (asterisks).
Table 3 MS-MLPA analytical sensitivity testing: analysis
of the samples dilution series ranging from 100%
to 2.5% of DNA from a full-mutated patient
Mixtures of dilution series FMR1 D*:U**
range
CI 95%
(l. inf. – l. sup.)
75% 0.47 – 0.88 0.432- 0.745
50% 0.32 – 0.65 0.316- 0.521
25% 0.17 – 0.3 0.178- 0.270
10% 0.06 – 0.14 0.323- 0.780
5% 0.04 – 0.09 0.111- 0.506
2.5% 0.00-0.08 0.001-0.062
*: digested with HhaI; ** undigested.
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undigested samples. Data Analysis was performed using
the Coffalyser software v. 9.4, able to calculate the nor-
malized ratios of HhaI digested to undigested peaks for
each of the FMR1 methylation-specific probes present
in each sample, according to Nygren [16].
SB analysis
In all patients, both in retrospective than in prospective
analysis, the FRAXA locus was analyzed with conven-
tional Southern analysis of genomic DNA (7 μg) digested
with the restriction enzymes EcoRI and EagI. The blotted
membranes were probed with a [32P]dCTP-labeled (Re-
divue; GE Healthcare Europe) StB12.3 probe that hybrid-
izes to the region from nucleotide 14461 to 15537 in
FMR1 (GenBank reference sequence L29074) [17].
Results
In all control samples and in the premutated male sam-
ple, MLPA analysis evidenced a peak ratio close to zeroFigure 3 MLPA Coffalyzer analysis: histogram shows a peak ratio = 0
3.2 Mb encompassing SLITRK2, FMR1 and FMR2 genes.for all the methylation sensitive probes, thus demon-
strating the absence of methylation in the FMR1 pro-
moter (Figure 1A-D; Table 2). In FXS male patients and
in CVS samples from full mutation fetuses, all FMR1
methylation sensitive probes showed a peak ratio value >
0.64 (Figure 1E,F; Table 2), indicating the presence of
an aberrant methylation of the FMR1 promoter, con-
cordant with the diagnosis of FXS previously assessed
by SB analysis. In the patient showing a size mosaicism
(pre/full), all the methylation sensitive probes of FMR1
showed a peak ratio ranging between 0.48 and 0.85
(Table 2); in this case densitometric analysis of SB had
shown that the signal of the methylated full mutation
was > 84% and the unmethylated premutation was
about 16% (data not shown). In the patient carrier of a
methylation mosaicism, MS-MLPA analysis evidenced a
peak ratio of FMR1 methylation sensitive probes ran-
ging between 0.04 and 0.08 (Figure 2A,B; Table 2). In
this particular case the SB analysis had shown that the
unmethylated full mutation smear was predominant
over the methylated one,that (as evidenced by densito-
metric analysis) was lower than 5% (data not shown).
On the other hand, MS-MLPA analysis on females
samples produced unreliable results, due to the presence
of an inactive, methylated X-chromosome generating
peak ratios overlapping among normal and full mutated
(Table 2).
To test the MLPA detection limit in the evaluation of
the methylated DNA levels, we performed a MS-MLPA
testing on a dilution series of samples ranging from
100% to 2.5% of DNA from a full mutation patient. This
experiment showed a proportional decrease of the peak
ratio value down to 5% of methylated DNA, while the
results obtained with the 2.5% dilution were not repro-in the deleted probes in the patient carrier of a microdeletion of
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methylated full mutation must represent at least 5% of
the total DNA in a sample to be detected by MS-MLPA,
indicating that this tool has an analytical sensitivity
lower than 100%, in agreement with previous results
reported by Abdool for the detection of mosaicisms of
copy number variation [18].
Finally, in order to test the MS-MLPA sensitivity on
deleted cases, we analysed a FXS patient carrier of a de-
letion detected by SB and validated by CGH [18]. MLPA
analysis confirmed the deletion showing a peak ratio = 0
of all specific probes for FMR1 and FMR2 (AFF2) genes
(Figure 3).
Discussion
The molecular diagnosis of FXS is a genetic routine test
increasingly required since the clinical diagnosis based
on dysmorphic features is quite subtle, especially in early
life. The SB analysis, so far considered the gold standard
test for both sizing of CGG repeat and assessing the
methylation status of the FMR1 gene promoter, is limited
by the necessity of large amounts of patient DNA, the
use of radioactive material and the low throughput. In
order to update our diagnostic approach to FXS, we set
up an internal procedure to validate the commercial kit
MS-MLPA SALSA ME029-B1 FMR1/AFF2, designed to
investigate both the methylation status of the FMR1
gene promoter and the gene copy number of the FRAXA
locus. Results provided by both the retrospective and the
prospective parts of this study demonstrate the robustness
and reproducibility of the MS-MLPA assay, that correctly
measured the methylation status in all normal and full
mutation male samples analyzed, including CVS male
samples. Thus, MS-MPLA can be considered as a useful
approach in the routinely molecular testing of the FMR1
gene, also considering that this assay represents a faster,
easier, low cost and high throughput technique as com-
pared to SB. However, the limits of MS-MLPA approach
in some specific cases must be discussed. The most crucial
issue related to the use of MS-MLPA assay remains the
possible presence of methylation mosaicisms. Our data
indicate that MS-MLPA is able to detect the presence
of a methylation mosaicism only when the methylated
DNA represents at least 5% of the total DNA in a sam-
ple, according to a previous report [16]. Thus, other
techniques, such as SB or mPCR are required in order
to assess the presence of very low level mosaicisms. On
the other hand, the size mosaicism appears to be cor-
rectly detectable by MS-MLPA assay, which in our case
produced an expected intermediate peak ratio ranging
from 0.48-0.85, according to the presence of 85% full
mutation.
Another limit of MS-MLPA is related to its application
in the study of FMR1 in females, where the random Xinactivation leads to results which are often borderline,
as previously reported [16].
Conclusion
Based on these results, we suggest the necessity of a
separate workflow for male and female patients with
suspected FXS in the routine diagnostic setting. In the
male patients we propose at first a PCR to evaluate the
presence of the specific fragment amplification and its
size calling. In the absence of amplification, when it is
necessary to analyse the gene methylation status, MS-
MLPA represents a reliable diagnostic protocol able to
replace SB in the majority of cases, except those showing
low levels methylation mosaicism. Since the MS-MLPA
kit ME029-B1 FMR1/AFF2 contains probes specific to
some other exons of the FMR1 gene as well as probes
specific to FMR2 gene, this probe mix is also useful to
identify the rare cases of deletions involving FMR1 gene,
as well as methylation status and deletions of FMR2
(AFF2) gene (FRAXE), providing a gain in the diagnostic
sensibility.
Also in female patients workflow the first step is re-
presented by PCR analysis for evidencing and eventually
sizing the presence of the two amplification fragments.
In case of only one amplification fragment it will be
necessary to discriminate between an homozygous wild
type allele or the presence of a normal allele and a pre-
or full- mutated one. Since MS-MLPA, as previously
discussed, is not reliable for these purposes in females,
the second step can be represented by classical SB or
by the recently proposed mPCR approach, combining
allele-specific methylation PCR and capillary electrophor-
esis, producing results concordant with corresponding
SB analyses [19].
In conclusion, the diagnostic scheme of FXS could be
modified as described, using Southern blotting only in
the few cases in which is really necessary and performing
PCR followed by MS-MLPA when a large number of pa-
tients needs to be analyzed in a routine setting, in order
to reduce both costs and time of the molecular analysis.
In this view, laboratories not performing Southern blot-
ting should be well aware of the limitations of the ap-
proach based on PCR/MLPA only, and should be able
to recognize cases to be referred to other labs capable
of doing Southern blotting.
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